grant
Targeting the cancer glycocalyx
Organization STANFORD UNIVERSITYLocation STANFORD, UNITED STATESPosted 1 Mar 2019Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY2026Acylneuraminyl hydrolaseAdhesion PlaquesAntibodiesBi-specific antibodiesBifunctional AntibodiesBindingBiologicalBispecific AntibodiesCancer ModelCancer PatientCancerModelCancersCathepsinsCell AdhesionCell BodyCell CoatCell Communication and SignalingCell Culture TechniquesCell Growth in NumberCell MultiplicationCell ProliferationCell SignalingCell SurvivalCell TherapyCell ViabilityCell surfaceCell-Matrix Adherens JunctionsCellsCellular AdhesionCellular ProliferationChimeraChimera organismCirculationClinical Treatment MoabDependenceDevelopmentDiseaseDisease ProgressionDisorderEngineeringEsteroproteasesFamilyFc domainFocal AdhesionsFocal ContactsFundingGlycansGlycocalyxGlycoconjugatesGlycoproteinsHumanHuman EngineeringImmuneImmune Cell SuppressionImmune EvasionImmune SurveillanceImmune mediated therapyImmunesImmunologic SurveillanceImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosurveillanceImmunotherapyIntracellular Communication and SignalingKnowledgeLectinLigandsMalignant CellMalignant NeoplasmsMalignant TumorMediatingMetabolic GlycosylationMiceMice MammalsModalityModelingModern ManMolecular InteractionMonoclonal AntibodiesMucinsMucus GlycoproteinMurineMusMyeloid CellsN-Acetylneuraminic AcidsN-Acylneuraminate GlycohydrolasesNeuraminidaseOligosaccharide SialidasePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatternPeptidasesPeptide HydrolasesPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePhase 2 Clinical TrialsPhase II Clinical TrialsPhenotypePolysaccharidesProliferatingProtease GeneProteasesProteinasesProteolytic EnzymesReceptor ProteinSialic AcidsSialidaseSignal TransductionSignal Transduction SystemsSignalingSpecificityStructureT-Cell ActivationT-CellsT-LymphocyteTestingTumor AntigensTumor-Associated AntigenVHHVHH antibodyWorkactivate T cellsantigen bindingantigen boundbi-specific T cell engagerbiologicbiological signal transductionbispecific T cell engagerbsAbcamelid antibodycamelid based antibodycamelid derived antibodycamelid derived fragmentcamelid heavy chain only Abscamelid immunoglobulincamelid single chain antibodycamelid variable heavy chaincancer antigenscancer cellcell based interventioncell culturecell culturescell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point receptorscheckpoint receptorschimerasclinical translationclinically translatabledevelopmentalexo alpha sialidaseglycosylationimmune evasiveimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseinventionmAbsmalignancymembermonoclonal Absmucinasenanobodiesnanobodyneoplasm/cancernew approachesnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel approachesnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachoverexpressoverexpressionpatient oriented outcomespharmaceuticalphase II protocolphysical propertypre-clinical developmentpreclinical developmentprogramsreceptorresponsesdAbsialic acid binding Ig-like lectinsiglecsingle domain antibodiessugartargeted cancer therapythymus derived lymphocytetumor-specific antigenvariable heavy chain antibody
Description preview
PROJECT SUMMARY
Altered cell-surface glycosylation is recognized as a hallmark of cancer. Two frequently observed cancer-
associated glyco-phenotypes are hypersialylation and mucin overexpression. These cancer glycosylation
patterns strongly correlate with disease aggressiveness and poor patient outcomes, but until recently their
functional…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click